Abstract
Despite tremendous scientific effort, conventional treatment approaches have had little impact on the course of pancreatic ductal adenocarcinoma. Therefore, urgency is needed to understand the molecular mechanisms underlying the development of pancreatic cancer with the hope that this will lead to preventative and treatment strategies to improve the outcome of the disease. Numerous factors contribute to progression of this disease, including constitutively active NFκB, which has been shown to positively influence cancer cell survival, proliferation, invasion, metastasis and chemoresistance. Recently, the cytoplasmic serine/threonine protein kinase glycogen synthase kinase-3β (GSK-3β) was found to regulate NFκB activation and the proliferation and survival of pancreatic cancer cells. Moreover, recent studies in other human malignancies have implicated GSK-3β as a regulator of cancer cell proliferation, survival and chemoresistance through distinct mechanisms. Thus, GSK-3β has emerged as a viable therapeutic target in the treatment of several human neoplasms.
Original language | English (US) |
---|---|
Pages (from-to) | 398-402 |
Number of pages | 5 |
Journal | Pancreatology |
Volume | 7 |
Issue number | 5-6 |
DOIs | |
State | Published - Oct 2007 |
Keywords
- Glycogen synthase
- Glycogen synthase kinase-3
- Heterochromatin
- NFκB
- Pancreatic adenocarcinoma
- β-Catenin
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Gastroenterology